Kyongbo Pharmaceutical Co., Ltd.

As of June 30, 2026, Kyongbo Pharmaceutical Co., Ltd. carries a market capitalization of 123.36B, placing it among publicly traded companies globally. Its enterprise value stands at 267.53B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Kyongbo Pharmaceutical Co., Ltd. has 23.91M shares outstanding.

As of June 30, 2026, Kyongbo Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 24.48. The price-to-sales ratio is 0.44, and the price-to-book ratio stands at 0.84.

As of June 30, 2026, Kyongbo Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 15.98 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.96 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 101.60 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 267.53B versus a market cap of 123.36B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Kyongbo Pharmaceutical Co., Ltd. maintains a current ratio of 0.88, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Kyongbo Pharmaceutical Co., Ltd. posted a return on equity (ROE) of 3.49, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 0.80 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.48, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 1.80, useful for judging operating efficiency across full business cycles. The company generates approximately 499.65M in revenue per employee across its workforce of 559.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.01 indicates how many times Kyongbo Pharmaceutical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Kyongbo Pharmaceutical Co., Ltd. recorded 931.95M in income tax expense. That works out to an effective tax rate of 15.60, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 5.98B, leaving 5.04B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Kyongbo Pharmaceutical Co., Ltd.'s stock has declined approximately 11.55% over the past 52 weeks. The 50-day moving average sits at 5,339.20, while the 200-day moving average is 5,804.90.

Over the twelve months ended June 30, 2026, Kyongbo Pharmaceutical Co., Ltd. generated 279.55B in revenue and converted that into 5.04B in net income, yielding earnings per share of 210.79. EBITDA reached 16.74B, while operating income came in at 2.63B.

As of June 30, 2026, Kyongbo Pharmaceutical Co., Ltd. holds 13.83B in cash and equivalents against 158.00B in total debt, resulting in a net debt position of 148.51B. Total book value stands at 146.99B, with working capital of -23.65B providing operational flexibility.

Kyongbo Pharmaceutical Co., Ltd. produced 11.95B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -57.33B in capital expenditures, free cash flow totaled -45.37B - equivalent to -1,896.41 per share.

Over the twelve months ended June 30, 2026, Kyongbo Pharmaceutical Co., Ltd. posted a gross margin of 38.44, reflecting its pricing power and cost economics. The operating margin of 0.94 and net profit margin of 1.80 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Kyongbo Pharmaceutical Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -36.75: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -34.91, meaning Kyongbo Pharmaceutical Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Kyongbo Pharmaceutical Co., Ltd. has an Altman Z-Score of 1.44, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.